Solution Structure of Human Cardiac Troponin C in Complex with the Green Tea Polyphenol, (?)-Epigallocatechin 3-Gallate

Heart muscle contraction is regulated by Ca²⁺ binding to the thin filament protein troponin C. In cardiovascular disease, the myofilament response to Ca²⁺ is often altered. Compounds that rectify this perturbation are of considerable interest as therapeutics. Plant flavonoids have been found to provide protection against a variety of human illnesses such as cancer, infection, and heart disease. (−)-Epigallocatechin gallate (EGCg), the prevalent flavonoid in green tea, modulates force generation in isolated guinea pig hearts (Hotta, Y., Huang, L., Muto, T., Yajima, M., Miyazeki, K., Ishikawa, N., Fukuzawa, Y., Wakida, Y., Tushima, H., Ando, H., and Nonogaki, T. (2006) Eur. J. Pharmacol. 552, 123–130) and in skinned cardiac muscle fibers (Liou, Y. M., Kuo, S. C., and Hsieh, S. R. (2008) Pflugers Arch. 456, 787–800; and Tadano, N., Yumoto, F., Tanokura, M., Ohtsuki, I., and Morimoto, S. (2005) Biophys. J. 88, 314a). In this study we describe the solution structure of the Ca²⁺-saturated C-terminal domain of troponin C in complex with EGCg. Moreover, we show that EGCg forms a ternary complex with the C-terminal domain of troponin C and the anchoring region of troponin I. The structural evidence indicates that the binding site of EGCg on the C-terminal domain of troponin C is in the hydrophobic pocket in the absence of troponin I, akin to EMD 57033. Based on chemical shift mapping, the binding of EGCg to the C-terminal domain of troponin C in the presence of troponin I may be to a new site formed by the troponin C·troponin I complex. This interaction of EGCg with the C-terminal domain of troponin C·troponin I complex has not been shown with other cardiotonic molecules and illustrates the potential mechanism by which EGCg modulates heart contraction.Cardiovascular disease (CVD)² is the number one cause of morbidity and mortality in western culture. In the United States, ∼1 in 3 deaths in 2004 were caused by CVD (1). In heart failure, the ability of the heart to distribute blood throughout the body is perturbed, and there is a growing interest to develop drugs that directly regulate the response of the myofilament to Ca²⁺. Regulation of muscle contraction is triggered by Ca²⁺ binding to troponin. The troponin complex is situated at regular intervals along the thin filament, which is made up of two elongated polymers, f-actin and tropomyosin. The backbone of the thin filament is composed of actin molecules arranged in a double helix with tropomyosin wound around actin as a coiled-coil. Anchored at every seventh actin molecule is the heterotrimeric troponin complex, which consists of troponin C (TnC), troponin I (TnI), and troponin T (TnT). TnC is the Ca²⁺-binding subunit of troponin and has four EF-hand helix-loop-helix motifs. TnI is the inhibitory subunit of troponin. It regulates the actin-myosin cross-bridge formation by flipping between TnC and actin in a Ca²⁺-dependent manner. At low levels of cytosolic Ca²⁺, TnI is bound to actin, causing tropomyosin to sterically block the binding of the actomyosin cross-bridges. On the other hand, when Ca²⁺ concentration is high, TnI translocates from actin to TnC inducing tropomyosin to change its orientation on actin so that the actin-myosin interaction may occur. The subunit TnT fetters the troponin complex to the thin filament by way of its association with TnI (for reviews on contraction see Refs. 2–5).The large number of structural studies on troponin and the thin filament has helped gain insight into the molecular mechanism of muscle contraction. TnC is a dumbbell-shaped protein that consists of terminal domains connected by an elongated flexible linker, as shown by solution NMR (6). The overall folds of the terminal domains of skeletal TnC (sTnC) and cardiac TnC (cTnC) are very similar (7–9). The apo state of the N-domain of sTnC (sNTnC) and cTnC (cNTnC) reveals that the domain is in a “closed” conformation, such that the hydrophobic core of the protein is buried (8, 10, 11). In the skeletal system, sNTnC “opens” when two Ca²⁺ ions bind (8, 10, 11). Alternatively, cNTnC contains only one functional Ca²⁺-binding site, and its global conformation does not change as significantly as in sNTnC (11). Nonetheless, Ca²⁺ binding promotes the association of the switch region of cTnI (residues 147–163) with cNTnC. cTnI-(147–163) forms an α-helix when associated with cNTnC and has been elucidated by NMR in the solution structure of cNTnC·Ca²⁺·cTnI-(147–163) (12) and by the x-ray crystallography structure of cTnC·3Ca²⁺·cTnI·-(31–210)·cTnT-(183–288) (13). The interaction of cTnI-(147–163) with cNTnC·Ca²⁺ is essential to draw the inhibitory (cTnI-(128–147)) and C-terminal (cTnI-(163–210)) regions of cTnI away from actin. cTnI-(128–147) is not visualized in the cardiac structure, probably due to disorder (13). In the skeletal crystal structure of sTnC·4Ca²⁺·sTnI-(1–182)·sTnT-(156–262), however, the inhibitory region of sTnI is visualized and makes electrostatic contacts with the central helix connecting the N- and C-terminal lobes of cTnC (14). The C-domain (CTnC) of both sTnC and cTnC has two functional binding sites for Ca²⁺ and remains largely unstructured without Ca²⁺ bound. The folding of this domain occurs in the presence of Ca²⁺ (15, 16). Throughout the relaxation-contraction cycle, cCTnC is Ca²⁺-saturated with both Ca²⁺-binding sites occupied (cCTnC·2Ca²⁺) and is associated with the anchoring region of cTnI (cTnI-(34–71)). The crystal structure of cTnC·3Ca²⁺·cTnI·-(31–210)·cTnT-(183–288) shows cTnI-(34–71) is α-helical when bound with cCTnC·2Ca²⁺(13). The interaction of cCTnC·2Ca²⁺ with cTnI-(34–71) is the primary site in which cTnC is tethered to the thin filament.In light of the importance of the Ca²⁺-dependent cTnI-cTnC interaction in the signaling of muscle contraction, the design of drugs that modulate this interaction would be useful in the treatment of heart disease. Compounds that treat CVD through modulation of the activity of cTnC are called Ca²⁺ sensitizers or desensitizers, depending on whether they positively or negatively influence its function. These drugs are safer than other currently prescribed medicines that alter the cytosolic Ca²⁺ homeostasis (such as milrinone and dobutamine), which may cause arrhythmia or death with prolonged usage.The potential therapeutic advantage of Ca²⁺ (de)sensitizers has led to the development of a number of compounds that target cTnC. Compounds have been identified that elicit their activity through binding either cNTnC or cCTnC. Levosimendan and pimobendan are examples of molecules that increase heart muscle contractility through binding to cNTnC. Conversely, the molecule W7 decreases contractility via its interaction with cNTnC. For recent reviews on the molecular mechanism of these compounds and others see Refs. 17–19. The discovery of small molecules that bind to cCTnC to elicit their Ca²⁺-sensitizing effects suggests that cCTnC is also a suitable target for the development of therapeutics. The Ca²⁺ sensitizer, EMD 57033, is approved for the treatment for heart failure in dogs and binds to cCTnC·2Ca²⁺(20). In the NMR structure of cCTnC·2Ca²⁺·EMD 57033, EMD 57033 is associated in the hydrophobic cavity of cCTnC·2Ca²⁺ (21). The interaction of EMD 57033 with cCTnC is stereospecific for the (+)-enantiomer and explains why the (−)-enantiomer is inactive (22). Because EMD 57033 has been shown to bind cCTnC·2Ca²⁺ concurrently with cTnI-(128–147) but not with cTnI-(34–71) (23), one postulate is that EMD 57033 acts as a Ca²⁺ sensitizer by weakening the interaction of cTnI-(34–71) with cCTnC·2Ca²⁺, thus increasing the propensity of cTnI-(128–147) to bind cCTnC·2Ca²⁺ in vivo. The dilated cardiomyopathy (DCM) mutation, G159D, of cCTnC has renewed interest in the role of the C-lobe for regulation in contraction. The mutation has been identified to decrease the sensitivity of the thin filament to Ca²⁺ (24). The source of the DCM phenotype of G159D might come from the modulation of the interaction of cCTnC·2Ca²⁺ with cTnI-(34–71) (25).Green tea (Camellia sinensis) is one of the most widely consumed beverages in the world, and several epidemiological studies have linked the consumption of tea with a decrease in CVD (26, 27). (−)-Epigallocatechin gallate (EGCg) is a polyphenol that exists abundantly in unfermented teas and has been identified as a modulator of heart contraction through its interaction with cTnC (28–30). Here we use NMR spectroscopy to elucidate the three-dimensional structure of the cCTnC·2Ca²⁺·EGCg complex. The solution structure reveals that EGCg binds at the hydrophobic core of cCTnC inducing a small structural “opening.” We also use two-dimensional NMR spectroscopy to monitor the binding of EGCg to cCTnC·2Ca²⁺ and cCTnC·2Ca²⁺·cTnI-(34–71). Because EGCg and cTnI-(34–71) can bind cCTnC concurrently, the inotropic effect of EGCg may stem from its modulation of the cTnI-(34–71)-cCTnC·2Ca²⁺ interaction. The solution structure of cCTnC·2Ca²⁺·EGCg provides insight into the mechanism in which EGCg might influence heart contraction. These results taken with previous research on the Ca²⁺ sensitizer EMD 57033 and the DCM mutation G159D bring into question the dogma that cNTnC is the exclusive site for regulation of contraction in cTnC.     

Kinetic Mechanism of Ca2+-controlled Changes of Skeletal Troponin I in Psoas Myofibrils

Conformational changes in the skeletal troponin complex (sTn) induced by rapidly increasing or decreasing the [Ca²⁺] were probed by 5-iodoacetamidofluorescein covalently bound to Cys-133 of skeletal troponin I (sTnI). Kinetics of conformational changes was determined for the isolated complex and after incorporating the complex into rabbit psoas myofibrils. Isolated and incorporated sTn exhibited biphasic Ca²⁺-activation kinetics. Whereas the fast phase (k_obs∼1000 s⁻¹) is only observed in this study, where kinetics were induced by Ca²⁺, the slower phase resembles the monophasic kinetics of sTnI switching observed in another study (Brenner and Chalovich. 1999. Biophys. J. 77:2692–2708) that investigated the sTnI switching induced by releasing the feedback of force-generating cross-bridges on thin filament activation. Therefore, the slower conformational change likely reflects the sTnI switch that regulates force development. Modeling reveals that the fast conformational change can occur after the first Ca²⁺ ion binds to skeletal troponin C (sTnC), whereas the slower change requires Ca²⁺ binding to both regulatory sites of sTnC. Incorporating sTn into myofibrils increased the off-rate and lowered the Ca²⁺ sensitivity of sTnI switching. Comparison of switch-off kinetics with myofibril force relaxation kinetics measured in a mechanical setup indicates that sTnI switching might limit the rate of fast skeletal muscle relaxation.     

Troponin I Mutations R146G and R21C Alter Cardiac Troponin Function,Contractile Properties,and Modulation by Protein Kinase A (PKA)-mediated Phosphorylation

Two hypertrophic cardiomyopathy-associated cardiac troponin I (cTnI) mutations, R146G and R21C, are located in different regions of cTnI, the inhibitory peptide and the cardiac-specific N terminus. We recently reported that these regions may interact when Ser-23/Ser-24 are phosphorylated, weakening the interaction of cTnI with cardiac TnC. Little is known about how these mutations influence the affinity of cardiac TnC for cTnI (K_C-I) or contractile kinetics during β-adrenergic stimulation. Here, we tested how cTnI^R146G or cTnI^R21C influences contractile activation and relaxation and their response to protein kinase A (PKA). Both mutations significantly increased Ca²⁺ binding affinity to cTn (K_Ca) and K_C-I. PKA phosphorylation resulted in a similar reduction of K_Ca for all complexes, but K_C-I was reduced only with cTnI^WT. cTnI^WT, cTnI^R146G, and cTnI^R21C were complexed into cardiac troponin and exchanged into rat ventricular myofibrils, and contraction/relaxation kinetics were measured ± PKA phosphorylation. Maximal tension (T_max) was maintained for cTnI^R146G- and cTnI^R21C-exchanged myofibrils, and Ca²⁺ sensitivity of tension (pCa₅₀) was increased. PKA phosphorylation decreased pCa₅₀ for cTnI^WT-exchanged myofibrils but not for either mutation. PKA phosphorylation accelerated the early slow phase relaxation for cTnI^WT myofibrils, especially at Ca²⁺ levels that the heart operates in vivo. Importantly, this effect was blunted for cTnI^R146G- and cTnI^R21C-exchanged myofibrils. Molecular dynamics simulations suggest both mutations inhibit formation of intra-subunit contacts between the N terminus and the inhibitory peptide of cTnI that is normally seen with WT-cTn upon PKA phosphorylation. Together, our results suggest that cTnI^R146G and cTnI^R21C blunt PKA modulation of activation and relaxation kinetics by prohibiting cardiac-specific N-terminal interaction with the cTnI inhibitory peptide.     

The Inotropic Effect of the Active Metabolite of Levosimendan,OR-1896, Is Mediated through Inhibition of PDE3 in Rat Ventricular Myocardium

Aims

We recently published that the positive inotropic response (PIR) to levosimendan can be fully accounted for by phosphodiesterase (PDE) inhibition in both failing human heart and normal rat heart. To determine if the PIR of the active metabolite OR-1896, an important mediator of the long-term clinical effects of levosimendan, also results from PDE3 inhibition, we compared the effects of OR-1896, a representative Ca²⁺ sensitizer EMD57033 (EMD), levosimendan and other PDE inhibitors.

Methods

Contractile force was measured in rat ventricular strips. PDE assay was conducted on rat ventricular homogenate. cAMP was measured using RII_epac FRET-based sensors.

Results

OR-1896 evoked a maximum PIR of 33±10% above basal at 1 μM. This response was amplified in the presence of the PDE4 inhibitor rolipram (89±14%) and absent in the presence of the PDE3 inhibitors cilostamide (0.5±5.3%) or milrinone (3.2±4.4%). The PIR was accompanied by a lusitropic response, and both were reversed by muscarinic receptor stimulation with carbachol and absent in the presence of β-AR blockade with timolol. OR-1896 inhibited PDE activity and increased cAMP levels at concentrations giving PIRs. OR-1896 did not sensitize the concentration-response relationship to extracellular Ca²⁺. Levosimendan, OR-1896 and EMD all increased the sensitivity to β-AR stimulation. The combination of either EMD and levosimendan or EMD and OR-1896 further sensitized the response, indicating at least two different mechanisms responsible for the sensitization. Only EMD sensitized the α₁-AR response.

Conclusion

The observed PIR to OR-1896 in rat ventricular strips is mediated through PDE3 inhibition, enhancing cAMP-mediated effects. These results further reinforce our previous finding that Ca²⁺ sensitization does not play a significant role in the inotropic (and lusitropic) effect of levosimendan, nor of its main metabolite OR-1896.     

Phosphoinositide-3-kinase/akt - dependent signaling is required for maintenance of [Ca2+]i,ICa, and Ca2+ transients in HL-1 cardiomyocytes

The phosphoinositide 3-kinases (PI3K/Akt) dependent signaling pathway plays an important role in cardiac function, specifically cardiac contractility. We have reported that sepsis decreases myocardial Akt activation, which correlates with cardiac dysfunction in sepsis. We also reported that preventing sepsis induced changes in myocardial Akt activation ameliorates cardiovascular dysfunction. In this study we investigated the role of PI3K/Akt on cardiomyocyte function by examining the role of PI3K/Akt-dependent signaling on [Ca²⁺]_i, Ca²⁺ transients and membrane Ca²⁺ current, I_Ca, in cultured murine HL-1 cardiomyocytes. {"type":"entrez-nucleotide","attrs":{"text":"LY294002","term_id":"1257998346","term_text":"LY294002"}}LY294002 (1–20 μM), a specific PI3K inhibitor, dramatically decreased HL-1 [Ca²⁺]_i, Ca²⁺ transients and I_Ca. We also examined the effect of PI3K isoform specific inhibitors, i.e. α (PI3-kinase α inhibitor 2; 2–8 nM); β (TGX-221; 100 nM) and γ (AS-252424; 100 nM), to determine the contribution of specific isoforms to HL-1 [Ca²⁺]_i regulation. Pharmacologic inhibition of each of the individual PI3K isoforms significantly decreased [Ca²⁺]_i, and inhibited Ca²⁺ transients. Triciribine (1–20 μM), which inhibits AKT downstream of the PI3K pathway, also inhibited [Ca²⁺]_i, and Ca²⁺ transients and I_Ca. We conclude that the PI3K/Akt pathway is required for normal maintenance of [Ca²⁺]_i in HL-1 cardiomyocytes. Thus, myocardial PI3K/Akt-PKB signaling sustains [Ca²⁺]_i required for excitation-contraction coupling in cardiomyoctyes.     

PKA Phosphorylation of Cardiac Troponin I Modulates Activation and?Relaxation Kinetics of Ventricular Myofibrils

Protein kinase A (PKA) phosphorylation of myofibril proteins constitutes an important pathway for β-adrenergic modulation of cardiac contractility and relaxation. PKA targets the N-terminus (Ser-23/24) of cardiac troponin I (cTnI), cardiac myosin-binding protein C (cMyBP-C) and titin. The effect of PKA-mediated phosphorylation on the magnitude of contraction has been studied in some detail, but little is known about how it modulates the kinetics of thin filament activation and myofibril relaxation as Ca²⁺ levels vary. Troponin C (cTnC) interaction with cTnI (C-I interaction) is a critical step in contractile activation that can be modulated by cTnI phosphorylation. We tested the hypothesis that altering C-I interactions by PKA, or by cTnI phosphomimetic mutations (S23D/S24D-cTnI), directly affects thin filament activation and myofilament relaxation kinetics. Rat ventricular myofibrils were isolated and endogenous cTn was exchanged with either wild-type cTnI, or S23D/S24D-cTnI recombinant cTn. Contractile mechanics were monitored at maximum and submaximal Ca²⁺ concentrations. PKA treatment of wild-type cTn or exchange of cTn containing S23D/S24D-cTnI resulted in an increase in the rate of early, slow phase of relaxation (k_REL,slow) and a decrease in its duration (t_REL,slow). These effects were greater for submaximal Ca²⁺ activated contractions. PKA treatment also reduced the rate of contractile activation (k_ACT) at maximal, but not submaximal Ca²⁺, and reduced the Ca²⁺ sensitivity of contraction. Using a fluorescent probe coupled to cTnC (C35S-IANBD), the Ca²⁺-cTn binding affinity and C-I interaction were monitored. Ca²⁺ binding to cTn (pCa₅₀) was significantly decreased when cTnI was phosphorylated by PKA (ΔpCa₅₀ = 0.31). PKA phosphorylation of cTnI also weakened C-I interaction in the presence of Ca²⁺. These data suggest that weakened C-I interaction, via PKA phosphorylation of cTnI, may slow thin filament activation and result in increased myofilament relaxation kinetics, the latter of which could enhance early phase diastolic relaxation during β-adrenergic stimulation.     

Insulin Protects Pancreatic Acinar Cells from Palmitoleic Acid-induced Cellular Injury

Acute pancreatitis is a serious and sometimes fatal inflammatory disease where the pancreas digests itself. The non-oxidative ethanol metabolites palmitoleic acid (POA) and POA-ethylester (POAEE) are reported to induce pancreatitis caused by impaired mitochondrial metabolism, cytosolic Ca²⁺ ([Ca²⁺]_i) overload and necrosis of pancreatic acinar cells. Metabolism and [Ca²⁺]_i are linked critically by the ATP-driven plasma membrane Ca²⁺-ATPase (PMCA) important for maintaining low resting [Ca²⁺]_i. The aim of the current study was to test the protective effects of insulin on cellular injury induced by the pancreatitis-inducing agents, ethanol, POA, and POAEE. Rat pancreatic acinar cells were isolated by collagenase digestion and [Ca²⁺]_i was measured by fura-2 imaging. An in situ [Ca²⁺]_i clearance assay was used to assess PMCA activity. Magnesium green (MgGreen) and a luciferase-based ATP kit were used to assess cellular ATP depletion. Ethanol (100 mm) and POAEE (100 μm) induced a small but irreversible Ca²⁺ overload response but had no significant effect on PMCA activity. POA (50–100 μm) induced a robust Ca²⁺ overload, ATP depletion, inhibited PMCA activity, and consequently induced necrosis. Insulin pretreatment (100 nm for 30 min) prevented the POA-induced Ca²⁺ overload, ATP depletion, inhibition of the PMCA, and necrosis. Moreover, the insulin-mediated protection of the POA-induced Ca²⁺ overload was partially prevented by the phosphoinositide-3-kinase (PI3K) inhibitor, {"type":"entrez-nucleotide","attrs":{"text":"LY294002","term_id":"1257998346","term_text":"LY294002"}}LY294002. These data provide the first evidence that insulin directly protects pancreatic acinar cell injury induced by bona fide pancreatitis-inducing agents, such as POA. This may have important therapeutic implications for the treatment of pancreatitis.     

Angiotensin-2-Mediated Ca2+ Signaling in the Retinal Pigment Epithelium: Role of Angiotensin-Receptor- Associated-Protein and TRPV2 Channel

Angiotensin II (AngII) receptor (ATR) is involved in pathologic local events such as neovascularisation and inflammation including in the brain and retina. The retinal pigment epithelium (RPE) expresses ATR in its AT1R form, angiotensin-receptor-associated protein (Atrap), and transient-receptor-potential channel-V2 (TRPV2). AT1R and Atrap co-localize to the basolateral membrane of the RPE, as shown by immunostaining. Stimulation of porcine RPE (pRPE) cells by AngII results in biphasic increases in intracellular free Ca²⁺inhibited by losartan. Xestospongin C (xest C) and U-73122, blockers of IP3R and PLC respectively, reduced AngII-evoked Ca²⁺response. RPE cells from Atrap^−/− mice showed smaller AngII-evoked Ca²⁺peak (by 22%) and loss of sustained Ca²⁺elevation compared to wild-type. The TRPV channel activator cannabidiol (CBD) at 15 µM stimulates intracellular Ca²⁺-rise suggesting that porcine RPE cells express TRPV2 channels. Further evidence supporting the functional expression of TRPV2 channels comes from experiments in which 100 µM {"type":"entrez-protein","attrs":{"text":"SKF96365","term_id":"1156357400","term_text":"SKF96365"}}SKF96365 (a TRPV channel inhibitor) reduced the cannabidiol-induced Ca²⁺-rise. Application of {"type":"entrez-protein","attrs":{"text":"SKF96365","term_id":"1156357400","term_text":"SKF96365"}}SKF96365 or reduction of TRPV2 expression by siRNA reduced the sustained phase of AngII-mediated Ca²⁺transients by 53%. Thus systemic AngII, an effector of the local renin-angiotensin system stimulates biphasic Ca²⁺transients in the RPE by releasing Ca²⁺from cytosolic IP3-dependent stores and activating ATR/Atrap and TRPV2 channels to generate a sustained Ca²⁺elevation.     

CGP37157, an inhibitor of the mitochondrial Na+/Ca2+ exchanger,protects neurons from excitotoxicity by blocking voltage-gated Ca2+ channels

Inhibition of the mitochondrial Na⁺/Ca²⁺ exchanger (NCLX) by {"type":"entrez-protein","attrs":{"text":"CGP37157","term_id":"875406365","term_text":"CGP37157"}}CGP37157 is protective in models of neuronal injury that involve disruption of intracellular Ca²⁺ homeostasis. However, the Ca²⁺ signaling pathways and stores underlying neuroprotection by that inhibitor are not well defined. In the present study, we analyzed how intracellular Ca²⁺ levels are modulated by {"type":"entrez-protein","attrs":{"text":"CGP37157","term_id":"875406365","term_text":"CGP37157"}}CGP37157 (10 μM) during NMDA insults in primary cultures of rat cortical neurons. We initially assessed the presence of NCLX in mitochondria of cultured neurons by immunolabeling, and subsequently, we analyzed the effects of {"type":"entrez-protein","attrs":{"text":"CGP37157","term_id":"875406365","term_text":"CGP37157"}}CGP37157 on neuronal Ca²⁺ homeostasis using cameleon-based mitochondrial Ca²⁺ and cytosolic Ca²⁺ ([Ca²⁺]_i) live imaging. We observed that NCLX-driven mitochondrial Ca²⁺ exchange occurs in cortical neurons under basal conditions as {"type":"entrez-protein","attrs":{"text":"CGP37157","term_id":"875406365","term_text":"CGP37157"}}CGP37157 induced a decrease in [Ca²]_i concomitant with a Ca²⁺ accumulation inside the mitochondria. In turn, {"type":"entrez-protein","attrs":{"text":"CGP37157","term_id":"875406365","term_text":"CGP37157"}}CGP37157 also inhibited mitochondrial Ca²⁺ efflux after the stimulation of acetylcholine receptors. In contrast, {"type":"entrez-protein","attrs":{"text":"CGP37157","term_id":"875406365","term_text":"CGP37157"}}CGP37157 strongly prevented depolarization-induced [Ca²⁺]_i increase by blocking voltage-gated Ca²⁺ channels (VGCCs), whereas it did not induce depletion of ER Ca²⁺ stores. Moreover, mitochondrial Ca²⁺ overload was reduced as a consequence of diminished Ca²⁺ entry through VGCCs. The decrease in cytosolic and mitochondrial Ca²⁺ overload by {"type":"entrez-protein","attrs":{"text":"CGP37157","term_id":"875406365","term_text":"CGP37157"}}CGP37157 resulted in a reduction of excitotoxic mitochondrial damage, characterized here by a reduction in mitochondrial membrane depolarization, oxidative stress and calpain activation. In summary, our results provide evidence that during excitotoxicity {"type":"entrez-protein","attrs":{"text":"CGP37157","term_id":"875406365","term_text":"CGP37157"}}CGP37157 modulates cytosolic and mitochondrial Ca²⁺ dynamics that leads to attenuation of NMDA-induced mitochondrial dysfunction and neuronal cell death by blocking VGCCs.     

Effect of bivalent cations on the adenosine triphosphatase of actomyosin and its modification by tropomyosin and troponin

1. After removal of tropomyosin and troponin from the `natural'' actomyosin complex, the adenosine triphosphatase activity of the resulting `desensitized'' actomyosin is stimulated to the same extent by various bivalent cations with an ionic radius in the range 0·65–0·99å when tested at optimum concentration of the metal ion in the presence of 2·5mm-ATP at low ionic strength and pH7·6. Under identical conditions the adenosine triphosphatase activity of myosin alone is stimulated to an appreciable extent only by Ca²⁺ (ionic radius 0·99å). 2. Tropomyosin narrows the range of size of the stimulatory cations by inhibiting specifically the adenosine triphosphatase activity of `desensitized'' actomyosin when stimulated by Ca<sup>2+</sup> or the slightly smaller Cd<sup>2+</sup> (ionic radius 0·97å). Tropomyosin has no effect on the adenosine triphosphatase activity of `desensitized'' actomyosin when stimulated by the smaller cations, nor on the Ca²⁺-activated adenosine triphosphatase activity of myosin alone. 3. The adenosine triphosphatase activity of the `natural'' actomyosin system (containing tropomyosin and troponin) stimulated by the smallest cation, Mg²⁺ (ionic radius 0·65å), is low when the system is deprived of Ca²⁺ but high in the presence of small amounts of Ca²⁺. This sensitivity to Ca²⁺ seems to be a unique feature of the Mg²⁺-stimulated system. 4. The changes in specificity of the myosin adenosine triphosphatase activity in its requirement for bivalent cations caused by interaction with actin, tropomyosin and troponin primarily concern the size of the metal ions. The effects on enzymic properties of myofibrils due to tropomyosin and troponin can be demonstrated at low and at physiological ionic strength.     

Identification of Leptospira interrogans Phospholipase C as a Novel Virulence Factor Responsible for Intracellular Free Calcium Ion Elevation during Macrophage Death

Background

Leptospira-induced macrophage death has been confirmed to play a crucial role in pathogenesis of leptospirosis, a worldwide zoonotic infectious disease. Intracellular free Ca²⁺ concentration ([Ca²⁺]i) elevation induced by infection can cause cell death, but [Ca²⁺]i changes and high [Ca²⁺]i-induced death of macrophages due to infection of Leptospira have not been previously reported.

Methodology/Principal Findings

We first used a Ca²⁺-specific fluorescence probe to confirm that the infection of L. interrogans strain Lai triggered a significant increase of [Ca²⁺]i in mouse J774A.1 or human THP-1 macrophages. Laser confocal microscopic examination showed that the [Ca²⁺]i elevation was caused by both extracellular Ca²⁺ influx through the purinergic receptor, P₂X₇, and Ca²⁺ release from the endoplasmic reticulum, as seen by suppression of [Ca²⁺]i elevation when receptor-gated calcium channels were blocked or P₂X₇ was depleted. The LB361 gene product of the spirochete exhibited phosphatidylinositol phospholipase C (L-PI-PLC) activity to hydrolyze phosphatidylinositol-4,5-bisphosphate (PIP₂) into inositol-1,4,5-trisphosphate (IP₃), which in turn induces intracellular Ca²⁺ release from endoplasmic reticulum, with the Km of 199 µM and Kcat of 8.566E-5 S^-1. Secretion of L-PI-PLC from the spirochete into supernatants of leptospire-macrophage co-cultures and cytosol of infected macrophages was also observed by Western Blot assay. Lower [Ca²⁺]i elevation was induced by infection with a LB361-deficient leptospiral mutant, whereas transfection of the LB361 gene caused a mild increase in [Ca²⁺]i. Moreover, PI-PLCs (PI-PLC-β3 and PI-PLC-γ1) of the two macrophages were activated by phosphorylation during infection. Flow cytometric detection demonstrated that high [Ca²⁺]i increases induced apoptosis and necrosis of macrophages, while mild [Ca²⁺]i elevation only caused apoptosis.

Conclusions/Significance

This study demonstrated that L. interrogans infection induced [Ca²⁺]i elevation through extracellular Ca²⁺ influx and intracellular Ca²⁺ release cause macrophage apoptosis and necrosis, and the LB361 gene product was shown to be a novel PI-PLC of L. interrogans responsible for the [Ca²⁺]i elevation.     

E-1020, a water soluble imidazopyridine,has direct effects on Ca2+-dependent force and ATP hydrolysis of canine and bovine cardiac myofilaments

E-1020 is a cardiotonic agent that acts as a cyclic-AMP phosphodiesterase inhibitor but also may have actions which alter myofilament response to Ca²⁺. To identify direct actions of E-1020 on cardiac contractile proteins, effects of E-1020 on myofibrillar Ca²⁺ dependent MgATPase and force generation in chemically skinned fiber bundles were measured. In bovine cardiac myofibrils, E-1020 (100 M) significantly increased myofilament Ca²⁺ sensitivity and Ca²⁺-dependent ATPase activity at submaximal pCa values. At pCa 6.75, E-1020 significantly increased ATPase activity in bovine (10–100 pM) and canine (1–100 pM) cardiac myofibrils but had no effect on rat cardiac myofibrils. Moreover, in one population of canine ventricular fiber bundles, E-1020 (0.0–10 M) significantly increased isometric tension at pCa 6.5 and 6.0, whereas in another population of bundles E-1020 had no effect on tension. In no case was resting (pCa 8.0) or maximal tension (pCa 4.5) increased by E-1020. Measurements of Ca²⁺ binding to canine ventricular skinned fiber preparations demonstrated that E-1020 does not alter the affinity of myofilament troponin C for Ca²⁺. We conclude that part of the mechanism by which E-1020 acts as an inotropic agent may involve alterations in the responsiveness of contractile proteins to Ca²⁺. The lack of effect of E-1020 on some preparations may be dependent on isoform populations of myofilament proteins.     

Epac1 mediates protein kinase A–independent mechanism of forskolin-activated intestinal chloride secretion

Intestinal Cl⁻ secretion is stimulated by cyclic AMP (cAMP) and intracellular calcium ([Ca²⁺]_i). Recent studies show that protein kinase A (PKA) and the exchange protein directly activated by cAMP (Epac) are downstream targets of cAMP. Therefore, we tested whether both PKA and Epac are involved in forskolin (FSK)/cAMP-stimulated Cl⁻ secretion. Human intestinal T84 cells and mouse small intestine were used for short circuit current (I_sc) measurement in response to agonist-stimulated Cl⁻ secretion. FSK-stimulated Cl⁻ secretion was completely inhibited by the additive effects of the PKA inhibitor, H89 (1 µM), and the [Ca²⁺]_i chelator, 1,2-bis-(o-aminophenoxy)-ethane-N,N,N’,N’-tetraacetic acid, tetraacetoxymethyl ester (BAPTA-AM; 25 µM). Both FSK and the Epac activator 8-pCPT-2’-O-Me-cAMP (50 µM) elevated [Ca²⁺]_i, activated Ras-related protein 2, and induced Cl⁻ secretion in intact or basolateral membrane–permeabilized T84 cells and mouse ileal sheets. The effects of 8-pCPT-2’-O-Me-cAMP were completely abolished by BAPTA-AM, but not by H89. In contrast, T84 cells with silenced Epac1 had a reduced I_sc response to FSK, and this response was completely inhibited by H89, but not by the phospholipase C inhibitor {"type":"entrez-nucleotide","attrs":{"text":"U73122","term_id":"4098075","term_text":"U73122"}}U73122 or BAPTA-AM. The stimulatory effect of 8-pCPT-2’-O-Me-cAMP on Cl⁻ secretion was not abolished by cystic fibrosis transmembrane conductance (CFTR) inhibitor 172 or glibenclamide, suggesting that CFTR channels are not involved. This was confirmed by lack of effect of 8-pCPT-2’-O-Me-cAMP on whole cell patch clamp recordings of CFTR currents in Chinese hamster ovary cells transiently expressing the human CFTR channel. Furthermore, biophysical characterization of the Epac1-dependent Cl⁻ conductance of T84 cells mounted in Ussing chambers suggested that this conductance was hyperpolarization activated, inwardly rectifying, and displayed a Cl⁻>Br⁻>I⁻ permeability sequence. These results led us to conclude that the Epac-Rap-PLC-[Ca²⁺]_i signaling pathway is involved in cAMP-stimulated Cl⁻ secretion, which is carried by a novel, previously undescribed Cl⁻ channel.     

Amiodarone Inhibits Apamin-Sensitive Potassium Currents

Background

Apamin sensitive potassium current (I _KAS), carried by the type 2 small conductance Ca²⁺-activated potassium (SK2) channels, plays an important role in post-shock action potential duration (APD) shortening and recurrent spontaneous ventricular fibrillation (VF) in failing ventricles.

Objective

To test the hypothesis that amiodarone inhibits I _KAS in human embryonic kidney 293 (HEK-293) cells.

Methods

We used the patch-clamp technique to study I _KAS in HEK-293 cells transiently expressing human SK2 before and after amiodarone administration.

Results

Amiodarone inhibited I_KAS in a dose-dependent manner (IC₅₀, 2.67±0.25 µM with 1 µM intrapipette Ca²⁺). Maximal inhibition was observed with 50 µM amiodarone which inhibited 85.6±3.1% of I_KAS induced with 1 µM intrapipette Ca²⁺ (n = 3). I_KAS inhibition by amiodarone was not voltage-dependent, but was Ca²⁺-dependent: 30 µM amiodarone inhibited 81.5±1.9% of I _KAS induced with 1 µM Ca²⁺ (n = 4), and 16.4±4.9% with 250 nM Ca²⁺ (n = 5). Desethylamiodarone, a major metabolite of amiodarone, also exerts voltage-independent but Ca²⁺ dependent inhibition of I _KAS.

Conclusion

Both amiodarone and desethylamiodarone inhibit I _KAS at therapeutic concentrations. The inhibition is independent of time and voltage, but is dependent on the intracellular Ca²⁺ concentration. SK2 current inhibition may in part underlie amiodarone''s effects in preventing electrical storm in failing ventricles.     

F?rster Resonance Energy Transfer Structural Kinetic Studies of Cardiac Thin Filament Deactivation

Cardiac thin filament deactivation is initiated by Ca²⁺ dissociation from troponin C (cTnC), followed by multiple structural changes of thin filament proteins. These structural transitions are the molecular basis underlying the thin filament regulation of cardiac relaxation, but the detailed mechanism remains elusive. In this study Förster resonance energy transfer (FRET) was used to investigate the dynamics and kinetics of the Ca²⁺-induced conformational changes of the cardiac thin filaments, specifically the closing of the cTnC N-domain, the cTnC-cTnI (troponin I) interaction, and the cTnI-actin interaction. The cTnC N-domain conformational change was examined by monitoring FRET between a donor (AEDANS) attached to one cysteine residue and an acceptor (DDPM) attached the other cysteine of the mutant cTnC(L13C/N51C). The cTnC-cTnI interaction was investigated by monitoring the distance changes from residue 89 of cTnC to residues 151 and 167 of cTnI, respectively. The cTnI-actin interaction was investigated by monitoring the distance changes from residues 151 and 167 of cTnI to residue 374 of actin. FRET Ca²⁺ titrations and stopped-flow kinetic measurements show that different thin filament structural transitions have different Ca²⁺ sensitivities and Ca²⁺ dissociation-induced kinetics. The observed structural transitions involving the regulatory region and the mobile domain of cTnI occurred at fast kinetic rates, whereas the kinetics of the structural transitions involving the cTnI inhibitory region was slow. Our results suggest that the thin filament deactivation upon Ca²⁺ dissociation is a two-step process. One step involves rapid binding of the mobile domain of cTnI to actin, which is kinetically coupled with the conformational change of the N-domain of cTnC and the dissociation of the regulatory region of cTnI from cTnC. The other step involves switching the inhibitory region of cTnI from interacting with cTnC to interacting with actin. The latter processes may play a key role in regulating cross-bridge kinetics.Cardiac muscle utilizes troponin to sense the concentration changes of myoplasmic Ca²⁺ and translate the transient Ca²⁺ signal into a cascade of events within the thin filament that ultimately leads to force generation or relaxation. The cardiac thin filament is composed of the heterotrimeric troponin complex and tropomyosin bound to the double helical actin filament (1, 2). The cardiac troponin is formed by three subunits: troponin C (cTnC),² troponin I (cTnI), and troponin T (cTnT). The subunit cTnC is the Ca²⁺-binding protein, cTnI binds actin and inhibits actomyosin ATPase in relaxed muscle, and cTnT anchors the troponin complex on the actin filament. A prominent feature of cardiac muscle regulation is the Ca²⁺-dependent dynamic interactions among the thin filament proteins and the multiple structural transitions at the interface between troponin and the actin filament. These structural transitions include opening/closing of the N-domain of cTnC (3, 4), changes in conformation of both the inhibitory region, and regulatory region of cTnI (5–7), switching of the inhibitory/regulatory regions of cTnI from interacting with actin to interacting with cTnC (8), and movement of tropomyosin on the actin surface (9), which permits cross-bridge cycling between actin and myosin. These Ca²⁺-induced structural transitions are the molecular basis of cardiac thin filament regulation. The strong cross-bridge formed between myosin heads and actin modulates the interactions among thin filament proteins and further affects thin filament regulation (10–12). This feedback has been identified as an important mechanism for the beat-to-beat regulation of cardiac output. However, the mechanism by which the thin filament regulation in cardiac muscle is fine tuned at a molecular level by cross-bridges remains to be determined.It has been suggested recently that the rate of myoplasmic Ca²⁺ removal does not rate limit contraction and relaxation of the muscle (13). For example, the mechanistic studies on cardiac trabeculae (14) and myofibrils (15, 16) suggest that Ca²⁺ binding to cTnC induced switching on of the thin filament regulatory unit well before force generation. In corroboration of the conclusion, de Tombe and co-workers (17) recently reported that changes in myofilament Ca²⁺ sensitivity do not affect the kinetics of myofibrillar contraction and relaxation, i.e. the cross-bridge cycling rate is independent of the dynamics of thin filament activation. This notion is consistent with findings from a recent study where Ca²⁺-induced conformational changes of cTnC were measured simultaneously with force development of myofibril (18). It was found that kinetics of the Ca²⁺-induced conformational change of cTnC was much faster than cross-bridge kinetics. However, one study using photolysis of caged Ca²⁺ reported that the rate of Ca²⁺-induced muscle contraction (k_Ca) was slower than the rate of force redevelopment (k_tr), suggesting the importance of the thin filament in regulating cross-bridge kinetics (19). These results raise questions as to how the thin filament regulation through Ca²⁺-cTnC interaction controls muscle contraction kinetics. If the kinetics of the cross-bridge formation and detachment determine the rate of cardiac muscle contraction and relaxation, what will be the regulatory role of thin filament in heart function? The fact is that a high percentage of cardiomyopathy mutations occur among the thin filament proteins, and some of these mutations can severely hinder the kinetics of heart contraction and relaxation (20). Without a link between Ca²⁺ regulation and dynamics of cross-bridge formation and detachment, it will be difficult to interpret the mechanism underlying how these mutations affect force development and relaxation in the diseased heart.Signal transduction of Ca²⁺ activation/deactivation along the thin filament involves multiple structural transitions of the thin filament proteins (21). Each structural transition may have different dynamics that can differ from Ca²⁺ exchange with cTnC. Therefore, the dynamics of these structural transitions within the thin filament may provide insight into the dynamic linkage between the Ca²⁺ binding to cTnC and the activation state of the cardiac thin filament. Time-resolved Förster resonance energy transfer (FRET), which can quantitate the distribution of inter-probe distances (22), provides a clear metric for study of Ca²⁺-induced structural changes (on Å scale) in the thin filament. FRET involves two fluorophores (one is the FRET donor and the other is an acceptor) attached to two different sites of proteins. Because FRET provides information on the conformational changes of proteins only around a specific region of interest, it is a unique approach for monitoring specific structural changes associated with the functional activities of the thin filament. Especially when combined with fast time-resolved techniques, FRET can provide dynamic and kinetic information associated with a specific structural transition in a multiple structural transition system (23–26).Accordingly, we focused our investigation on the relaxation kinetics of (a) cTnC N-domain closing, (b) cTnC-cTnI interaction, and (c) cTnI-actin interaction within the reconstituted thin filament upon Ca²⁺ removal from the regulatory binding site of cTnC. The kinetics of these structural transitions were measured using FRET stopped-flow to monitor structural changes associated with each transition in the reconstituted thin filament in the absence and presence of strongly bound myosin subfragment 1 (S1). Our results showed that all structural transitions occurred in two phases, one fast and the other slow. The fast phase transition accounted for more than two-thirds of the total FRET change, and the slow phase transition accounted for less than one-third of the total FRET change. Our study suggests that different structural transitions have different kinetics upon Ca²⁺ removal from cTnC. Structural transitions associated with the mobile domain and the regulatory region of cTnI occur at fast kinetic rates, whereas the structural transitions involving transversal movement of the inhibitory region of cTnI occur at slow rates.     

Prolonged calcium influx after termination of light-induced calcium release in invertebrate photoreceptors

In microvillar photoreceptors, light stimulates the phospholipase C cascade and triggers an elevation of cytosolic Ca²⁺ that is essential for the regulation of both visual excitation and sensory adaptation. In some organisms, influx through light-activated ion channels contributes to the Ca²⁺ increase. In contrast, in other species, such as Lima, Ca²⁺ is initially only released from an intracellular pool, as the light-sensitive conductance is negligibly permeable to calcium ions. As a consequence, coping with sustained stimulation poses a challenge, requiring an alternative pathway for further calcium mobilization. We observed that after bright or prolonged illumination, the receptor potential of Lima photoreceptors is followed by the gradual development of an after-depolarization that decays in 1–4 minutes. Under voltage clamp, a graded, slow inward current (I_slow) can be reproducibly elicited by flashes that saturate the photocurrent, and can reach a peak amplitude in excess of 200 pA. I_slow obtains after replacing extracellular Na⁺ with Li⁺, guanidinium, or N-methyl-d-glucamine, indicating that it does not reflect the activation of an electrogenic Na/Ca exchange mechanism. An increase in membrane conductance accompanies the slow current. I_slow is impervious to anion replacements and can be measured with extracellular Ca²⁺ as the sole permeant species; Ba can substitute for Ca²⁺ but Mg²⁺ cannot. A persistent Ca²⁺ elevation parallels I_slow, when no further internal release takes place. Thus, this slow current could contribute to sustained Ca²⁺ mobilization and the concomitant regulation of the phototransduction machinery. Although reminiscent of the classical store depletion–operated calcium influx described in other cells, I_slow appears to diverge in some significant aspects, such as its large size and insensitivity to {"type":"entrez-protein","attrs":{"text":"SKF96365","term_id":"1156357400","term_text":"SKF96365"}}SKF96365 and lanthanum; therefore, it may reflect an alternative mechanism for prolonged increase of cytosolic calcium in photoreceptors.     

Purification and some physico-chemical and enzymic properties of a calcium ion-activated neutral proteinase from rabbit skeletal muscle

Ca²⁺-activated neutral proteinase was purified from rabbit skeletal muscle by a method involving DEAE-Sephacel chromatography, affinity chromatography on organomercurial–Sepharose and gel filtration on Sephacryl S-200 and Sephadex G-150. The SDS (sodium dodecyl sulphate)/polyacrylamide-gel-electrophoresis data show that the purified enzyme contains only one polypeptide chain of mol.wt. 73000. The purification procedure used allowed us to eliminate a contaminant containing two components of mol.wt. about 30000 each. Whole casein or α₁-casein were hydrolysed with a maximum rate at 30°C, pH7.5, and with 5mm-CaCl₂, but myofibrils were found to be a very susceptible substrate for this proteinase. This activity is associated with the destruction of the Z-discs, which is caused by the solubilization of the Z-line proteins. The activity of the proteinase in vitro is not limited to the removal of Z-line. SDS/polyacrylamide-gel electrophoresis on larger plates showed the ability of the proteinase to degrade myofibrils more extensively than previously supposed. This proteolysis resulted in the production of a 30000-dalton component as well as in various other higher- and lower-molecular-weight peptide fragments. Troponin T, troponin I, α-tropomyosin, some high-molecular-weight proteins (M protein, heavy chain of myosin) and three unidentified proteins are degraded. Thus the number of proteinase-sensitive regions in the myofibrils is greater than as previously reported by Dayton, Goll, Zeece, Robson & Reville [(1976) Biochemistry 15, 2150–2158]. The Ca²⁺-activated neutral proteinase is not a chymotrypsin- or trypsin-like enzyme, but it reacted with all the classic thiol-proteinase inhibitors for cathepsin B, papain, bromelain and ficin. Thus the proteinase was proved to have an essential thiol group. Antipain and leupeptin are also inhibitors of the Ca²⁺-activated neutral proteinase.     

Arylbenzazepines Are Potent Modulators for the Delayed Rectifier K+ Channel: A Potential Mechanism for Their Neuroprotective Effects

(±) {"type":"entrez-protein","attrs":{"text":"SKF83959","term_id":"1155968032","term_text":"SKF83959"}}SKF83959, like many other arylbenzazepines, elicits powerful neuroprotection in vitro and in vivo. The neuroprotective action of the compound was found to partially depend on its D₁-like dopamine receptor agonistic activity. The precise mechanism for the (±) {"type":"entrez-protein","attrs":{"text":"SKF83959","term_id":"1155968032","term_text":"SKF83959"}}SKF83959-mediated neuroprotection remains elusive. We report here that (±) {"type":"entrez-protein","attrs":{"text":"SKF83959","term_id":"1155968032","term_text":"SKF83959"}}SKF83959 is a potent blocker for delayed rectifier K⁺ channel. (±) {"type":"entrez-protein","attrs":{"text":"SKF83959","term_id":"1155968032","term_text":"SKF83959"}}SKF83959 inhibited the delayed rectifier K⁺ current (I _K) dose-dependently in rat hippocampal neurons. The IC ₅₀ value for inhibition of I _K was 41.9±2.3 µM (Hill coefficient = 1.81±0.13, n = 6), whereas that for inhibition of I _A was 307.9±38.5 µM (Hill coefficient = 1.37±0.08, n = 6). Thus, (±) {"type":"entrez-protein","attrs":{"text":"SKF83959","term_id":"1155968032","term_text":"SKF83959"}}SKF83959 is 7.3-fold more potent in suppressing I _K than I _A. Moreover, the inhibition of I _K by (±) {"type":"entrez-protein","attrs":{"text":"SKF83959","term_id":"1155968032","term_text":"SKF83959"}}SKF83959 was voltage-dependent and not related to dopamine receptors. The rapidly onset of inhibition and recovery suggests that the inhibition resulted from a direct interaction of (±) {"type":"entrez-protein","attrs":{"text":"SKF83959","term_id":"1155968032","term_text":"SKF83959"}}SKF83959 with the K⁺ channel. The intracellular application of (±) {"type":"entrez-protein","attrs":{"text":"SKF83959","term_id":"1155968032","term_text":"SKF83959"}}SKF83959 had no effects of on I _K, indicating that the compound most likely acts at the outer mouth of the pore of K⁺ channel. We also tested the enantiomers of (±) {"type":"entrez-protein","attrs":{"text":"SKF83959","term_id":"1155968032","term_text":"SKF83959"}}SKF83959, R-(+) {"type":"entrez-protein","attrs":{"text":"SKF83959","term_id":"1155968032","term_text":"SKF83959"}}SKF83959 (MCL-201), and S-(−) {"type":"entrez-protein","attrs":{"text":"SKF83959","term_id":"1155968032","term_text":"SKF83959"}}SKF83959 (MCL-202), as well as {"type":"entrez-protein","attrs":{"text":"SKF38393","term_id":"1157151916","term_text":"SKF38393"}}SKF38393; all these compounds inhibited I _K. However, (±) {"type":"entrez-protein","attrs":{"text":"SKF83959","term_id":"1155968032","term_text":"SKF83959"}}SKF83959, at either 0.1 or 1 mM, exhibited the strongest inhibition on the currents among all tested drug. The present findings not only revealed a new potent blocker of I _K , but also provided a novel mechanism for the neuroprotective action of arylbenzazepines such as (±) {"type":"entrez-protein","attrs":{"text":"SKF83959","term_id":"1155968032","term_text":"SKF83959"}}SKF83959.     

Computational Studies of the Effect of the S23D/S24D Troponin I Mutation on Cardiac Troponin Structural Dynamics

During β-adrenergic stimulation, cardiac troponin I (cTnI) is phosphorylated by protein kinase A (PKA) at sites S23/S24, located at the N-terminus of cTnI. This phosphorylation has been shown to decrease K_Ca and pCa₅₀, and weaken the cTnC-cTnI (C-I) interaction. We recently reported that phosphorylation results in an increase in the rate of early, slow phase of relaxation (k_REL,slow) and a decrease in its duration (t_REL,slow), which speeds up the overall relaxation. However, as the N-terminus of cTnI (residues 1–40) has not been resolved in the whole cardiac troponin (cTn) structure, little is known about the molecular-level behavior within the whole cTn complex upon phosphorylation of the S23/S24 residues of cTnI that results in these changes in function. In this study, we built up the cTn complex structure (including residues cTnC 1–161, cTnI 1–172, and cTnT 236–285) with the N-terminus of cTnI. We performed molecular-dynamics (MD) simulations to elucidate the structural basis of PKA phosphorylation-induced changes in cTn structure and Ca²⁺ binding. We found that introducing two phosphomimic mutations into sites S23/S24 had no significant effect on the coordinating residues of Ca²⁺ binding site II. However, the overall fluctuation of cTn was increased and the C-I interaction was altered relative to the wild-type model. The most significant changes involved interactions with the N-terminus of cTnI. Interestingly, the phosphomimic mutations led to the formation of intrasubunit interactions between the N-terminus and the inhibitory peptide of cTnI. This may result in altered interactions with cTnC and could explain the increased rate and decreased duration of slow-phase relaxation seen in myofibrils.